Innovating Works

EVCYT

Desconocido
LIFESAVER: Living Impact on Fetal Evolution Shelter Analyze Validate Empower Regulations EVERCYTE GMBH participó en un H2020 H2020-LC-GD-2020 In Europe about 75% of all neonatal deaths and 60% of all infant deaths occur in infants born preterm, and worldwide 450 neonatal deaths occ...
2021-09-28 - 2025-10-31 | Financiado
in3: An integrated interdisciplinary approach to animal free chemical and nanomaterial safety assessment EVERCYTE GMBH participó en un H2020 H2020-MSCA-ITN-2016 All chemicals whether they are drugs, cosmetics, agrochemicals or others need to be tested for their safety to man and the environment. The...
2016-08-31 - 2021-06-30 | Financiado
eCHO Systems: Enhancing CHO by Mammalian Systems Biotechnology eCHO systems EVERCYTE GMBH participó en un H2020 H2020-MSCA-ITN-2014 Chinese hamster (CHO) ovary cells are the production host for a +50 billion €/yr biopharmaceuticals market. Current CHO production platforms...
2014-12-05 - 2018-12-31 | Financiado
FRAILOMIC: Utility of omic based biomarkers in characterizing older individuals at risk for frailty its progre... EVERCYTE GMBH participó en un FP7 The forecasted increase in the number of older people for this century will be accompanied by an increase of those with disabilities. Disabi...
Financiado
NANOII: Nanoscopically guided induction and expansion of regulatory hematopoietic cells to treat autoimmune... EVERCYTE GMBH participó en un FP7 We propose a multidisciplinary program, focusing on the development of novel approaches for directing the differentiation, proliferation and...
Financiado
SYBIL: Systems biology for the functional validation of genetic determinants of skeletal diseases EVERCYTE GMBH participó en un FP7 "The aim of SYBIL is to carry out extensive functional validation of the genetic determinants of rare and common skeletal diseases and the a...
Financiado
NANOCARD: Nanopatterned scaffolds for active myocardial implants EVERCYTE GMBH participó en un FP7 Cell therapy and tissue engineering are emerging as novel therapeutic paradigms for myocardial repair. The rationale behind the cell replace...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.